Company: STAA
Filing Date: 2025-11-07
Form Type: DEFA14A
Source: 0001193125-25-271794
Chunk: 18

Company: STAAR SURGICAL CO
Filing Date: 2025-11-07
Form: DEFA14A
Chunk 18
---
 a proposal.                                                                                                                                                                            |

Stephen Farrell, CEO of STAAR, said, “The STAAR Board continues to be committed to maximizing stockholder value. This go-shophas provisions that encourage all potential buyers to come forward to provide their updated perspectives on valuation based on our most recent financial results and business trends. This go-shopprocess will either produce a superior proposal or it will validate the merits of our proposed merger with Alcon. Either way, STAAR stockholders win.”

Mr. Farrell continued, “We look forward to continuing our dialogue with our stockholders during
this period. In addition, we are pleased that Alcon has committed to begin engaging with STAAR stockholders and proxy advisory firms to understand their perspectives on valuation and other aspects of the Alcon merger proposal.”

Special Meeting of Stockholders

In connection with the
amended merger agreement and new 30-day go-shop provision, STAAR has postponed the Special Meeting of Stockholders to vote on the Alcon merger proposal until after the go-shop period has expired. The Special Meeting was previously scheduled to be held on December 3, 2025 at 8:30 a.m. Pacific Time. STAAR has postponed the Special Meeting to December 19, 2025 at 8:30 a.m.
Pacific Time. STAAR stockholders of record as of the close of business on October 24, 2025 will be entitled to vote at the Special Meeting. STAAR will be providing a new notice of the Special Meeting to such stockholders in advance of the
December 19, 2025 Special Meeting.

Stockholders with questions about voting their shares should contact STAAR’s proxy solicitor, Innisfree
M&A Incorporated, toll-free at +1 877-750-8233. Banks and brokerage firms, please call +1
212-750-5833.

About STAAR Surgical

STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need
for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICL’s are clinically-proven to deliver safe long-term vision correction without removing corneal tissue or the
eye’s natural crystalline lens.